Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomySodium phosphate, monobasic
Identification
- Name
- Sodium phosphate, monobasic
- Accession Number
- DB09449 (DB09127, DB11083, DB09524, DB09542, DB09468, DB11084, DB09482, DB09469, DB09525, DBSALT001969)
- Type
- Small Molecule
- Groups
- Approved
- Description
Sodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.
- Structure
Structure for Sodium phosphate, monobasic (DB09449)
- Synonyms
- Disodium hydrogen phosphate anhydrous
- Monosodium dihydrogen monophosphate
- Monosodium dihydrogen orthophosphate
- Monosodium monophosphate
- Monosodium phosphate, anhydrous
- Phosphoric acid, monosodium salt, anhydrous
- Sodium acid phosphate
- Sodium biphosphate, anhydrous
- Sodium dihydrogen phosphate, anhydrous
- Sodium orthophosphate
- Sodium orthophosphate monobasic
- Sodium phosphate monobasic
- Sodium phosphate monobasic (anhydrate)
- Sodium phosphate monobasic (anhydrous)
- Sodium phosphate, monobasic
- Sodium phosphate, monobasic anhydrous
- Sodium phosphate,monobasic
- Sodium primary phosphate
- External IDs
- E-339(I) / INS NO.339(I) / INS-339(I)
- Product Ingredients
Ingredient UNII CAS InChI Key Sodium phosphate, monobasic, dihydrate 5QWK665956 13472-35-0 VBJGJHBYWREJQD-UHFFFAOYSA-M Sodium phosphate, monobasic, monohydrate 593YOG76RN 10049-21-5 BBMHARZCALWXSL-UHFFFAOYSA-M - Active Moieties
Name Kind UNII CAS InChI Key Phosphoric acid unknown E4GA8884NN 7664-38-2 NBIIXXVUZAFLBC-UHFFFAOYSA-N Sodium cation ionic LYR4M0NH37 17341-25-2 FKNQFGJONOIPTF-UHFFFAOYSA-N Phosphate ion ionic NK08V8K8HR 14265-44-2 NBIIXXVUZAFLBC-UHFFFAOYSA-K - Product Images
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Additive Formula 3 Sodium phosphate, monobasic, monohydrate (0.28 g/100mL) + Adenine (0.03 g/100mL) + Citric acid monohydrate (0.42 g/100mL) + D-glucose monohydrate (1.1 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL) + Sodium chloride (0.41 g/100mL) Solution Intravenous Terumo Bct, Ltd 2002-05-29 Not applicable US 
Additive Formula 3 Sodium phosphate, monobasic, monohydrate (0.28 g/100mL) + Adenine (0.03 g/100mL) + Citric acid monohydrate (0.42 g/100mL) + D-glucose monohydrate (1.1 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL) + Sodium chloride (0.41 g/100mL) Solution Intravenous Terumo Bct, Ltd 2002-05-29 Not applicable US Additive Formula 3 Sodium phosphate, monobasic, monohydrate (0.28 g/100mL) + Adenine (0.03 g/100mL) + Citric acid monohydrate (0.42 g/100mL) + D-glucose monohydrate (1.1 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL) + Sodium chloride (0.41 g/100mL) Solution Intravenous Terumo Bct, Ltd 2002-05-29 Not applicable US Additive Solution Formula 3 As-3 Sodium phosphate, monobasic, monohydrate (0.276 g) + Adenine (0.030 g) + Citric acid monohydrate (0.042 g) + Dextrose, unspecified form (1.10 g) + Sodium citrate dihydrate (0.588 g) + Sodium chloride (0.410 g) Solution Unknown Terumo Bct, Inc. 2013-05-31 Not applicable Canada 
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic) Sodium phosphate, monobasic, monohydrate (140 mg/63mL) + Adenine (27 mg/100mL) + Citric Acid (188 mg/63mL) + D-glucose monohydrate (1.61 g/63mL) + D-glucose monohydrate (2.2 g/100mL) + Mannitol (750 mg/100mL) + Sodium citrate dihydrate (1.66 g/63mL) + Sodium chloride (900 mg/100mL) Kit Fenwal, Inc. 2007-03-01 Not applicable US ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic) Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) + Sodium chloride (990 mg/110mL) Kit Fenwal, Inc. 2007-03-01 Not applicable US ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic) Sodium phosphate, monobasic, monohydrate (140 mg/63mL) + Adenine (27 mg/100mL) + Citric Acid (188 mg/63mL) + D-glucose monohydrate (1.61 g/63mL) + D-glucose monohydrate (2.2 g/100mL) + Mannitol (750 mg/100mL) + Sodium citrate dihydrate (1.66 g/63mL) + Sodium chloride (900 mg/100mL) Kit Fenwal, Inc. 2010-05-25 Not applicable US ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic) Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) + Sodium chloride (990 mg/110mL) Kit Fenwal, Inc. 2007-03-01 Not applicable US ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic) Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) + Sodium chloride (990 mg/110mL) Kit Fenwal, Inc. 2007-03-01 Not applicable US ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic) Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) + Sodium chloride (990 mg/110mL) Kit Fenwal, Inc. 2007-06-06 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Azuphen Mb Sodium phosphate, monobasic, monohydrate (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (120 mg/1) + Methylene blue trihydrate (10 mg/1) + Phenyl salicylate (36 mg/1) Capsule Oral Burel Pharmaceuticals, Llc 2015-09-28 2016-11-01 US Darpaz Sodium phosphate, monobasic (40.8 mg/1) + Hyoscyamine sulfate dihydrate (.12 mg/1) + Methenamine (81 mg/1) + Methylene blue trihydrate (10.8 mg/1) + Phenyl salicylate (32.4 mg/1) Tablet Oral River's Edge Pharmaceuticals, LLC 2008-12-01 2011-05-31 US Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1) Tablet Oral Kaiser Foundations Hospitals 2014-07-07 Not applicable US Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1) Tablet Oral American Health Packaging 2014-05-13 Not applicable US Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1) Tablet Oral Carilion Materials Management 2012-06-28 Not applicable US 
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1) Tablet Oral Rising Pharmaceuticals, Inc. 2012-06-28 Not applicable US Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1) Tablet Oral Cardinal Health 2012-06-28 2018-05-17 US 
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1) Tablet Oral Avera McKennan Hospital 2015-03-11 2018-06-05 US 
Hyolev Mb Sodium phosphate, monobasic, monohydrate (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (81 mg/1) + Methylene blue trihydrate (10.8 mg/1) + Phenyl salicylate (32.4 mg/1) Tablet Oral Burel Pharmaceuticals, Llc 2015-06-26 2016-11-01 US Indiomin Mb Sodium phosphate, monobasic, monohydrate (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (120 mg/1) + Methylene blue trihydrate (10 mg/1) Capsule Oral Burel Pharmaceuticals, Llc 2015-09-28 2016-10-24 US - Categories
- UNII
- KH7I04HPUU
- CAS number
- 7558-80-7
- Weight
- Average: 119.977
Monoisotopic: 119.958839739 - Chemical Formula
- H2NaO4P
- InChI Key
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M
- InChI
- InChI=1S/Na.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+1;/p-1
- IUPAC Name
- sodium dihydrogen phosphate
- SMILES
- [Na+].OP(O)([O-])=O
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Pharmacology
- Indication
Used to treat constipation or to clean the bowel before a colonoscopy [Label].
- Associated Conditions
- Associated Therapies
- Pharmacodynamics
Sodium phosphate inceases fecal water content to increase mobility through the large intestine [1].
- Mechanism of action
Sodium phosphate is thought to work by increasing the amount of solute present in the intestinal lumen thereby creating an osmotic gradient which draws water into the lumen [1].
- Absorption
Tmax for phosphate absorption with orally administered liquid sodium phosphate is 1-3h [3].
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
Intamuscular LD50 of 250mg/kg and oral LD50 of 8290 mg/kg reported in rats [7]. Phosphate toxicity is likely due to the disturbance of other electrolytes when phosphate levels are high, producing symptoms including tetany, dehydration, hypotension, tachycardia, hyperpyrexia, cardiac arrest and coma [4]. Risk of raising phosphate levels through use of sodium phosphate appears to be higher in smaller patients [3].
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid The risk or severity of nephrotoxicity can be increased when 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid is combined with Sodium phosphate, monobasic. 2,5-Dimethoxy-4-ethylamphetamine The serum concentration of 2,5-Dimethoxy-4-ethylamphetamine can be decreased when it is combined with Sodium phosphate, monobasic. 2,5-Dimethoxy-4-ethylthioamphetamine The serum concentration of 2,5-Dimethoxy-4-ethylthioamphetamine can be decreased when it is combined with Sodium phosphate, monobasic. 4-Bromo-2,5-dimethoxyamphetamine The serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when it is combined with Sodium phosphate, monobasic. 7-Nitroindazole The therapeutic efficacy of 7-Nitroindazole can be decreased when used in combination with Sodium phosphate, monobasic. Acebutolol Sodium phosphate, monobasic may increase the hyperkalemic activities of Acebutolol. Aceclofenac The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Aceclofenac. Acemetacin The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Acemetacin. Acetazolamide Acetazolamide may increase the nephrotoxic activities of Sodium phosphate, monobasic. Acetylsalicylic acid The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Acetylsalicylic acid. - Food Interactions
- Not Available
References
- General References
- Rex DK: Dosing considerations in the use of sodium phosphate bowel preparations for colonoscopy. Ann Pharmacother. 2007 Sep;41(9):1466-75. Epub 2007 Jul 24. [PubMed:17652123]
- Schanz S, Kruis W, Mickisch O, Kuppers B, Berg P, Frick B, Heiland G, Huppe D, Schenck B, Horstkotte H, Winkler A: Bowel Preparation for Colonoscopy with Sodium Phosphate Solution versus Polyethylene Glycol-Based Lavage: A Multicenter Trial. Diagn Ther Endosc. 2008;2008:713521. doi: 10.1155/2008/713521. [PubMed:18645612]
- Ehrenpreis ED: Increased serum phosphate levels and calcium fluxes are seen in smaller individuals after a single dose of sodium phosphate colon cleansing solution: a pharmacokinetic analysis. Aliment Pharmacol Ther. 2009 Jun 1;29(11):1202-11. doi: 10.1111/j.1365-2036.2009.03987.x. Epub 2009 Feb 27. [PubMed:19298584]
- Razzaque MS: Phosphate toxicity: new insights into an old problem. Clin Sci (Lond). 2011 Feb;120(3):91-7. doi: 10.1042/CS20100377. [PubMed:20958267]
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
- FDA Guide: Sodium Phosphate Tablet [Link]
- ChemIDPlus: Sodium Phosphate [Link]
- External Links
- PubChem Compound
- 23672064
- PubChem Substance
- 347827853
- ChemSpider
- 22626
- ChEBI
- 37585
- ChEMBL
- CHEMBL1368
- Wikipedia
- Sodium_phosphates
- FDA label
- Download (359 KB)
- MSDS
- Download (84.7 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Prevention Plasmodium Infections 1 2 Completed Basic Science Colonoscopy 1 2 Completed Screening Healthy Volunteers 1 3 Active Not Recruiting Treatment X-Linked Hypophosphatemia 1 3 Completed Not Available Colonoscopy 1 3 Completed Diagnostic Bowel Preparation, Efficacy, Tolerability, Safety 1 3 Completed Treatment Cataracts 2 3 Completed Treatment Colon Cleansing 1 3 Completed Treatment Colonoscopy 2 4 Completed Not Available Eye Dryness 1 4 Completed Diagnostic Colonoscopy 1 4 Completed Other Sickle Cell Disorders 1 4 Completed Treatment Colon Cleansing 1 4 Completed Treatment Colonoscopy 2 4 Completed Treatment Colorectal Cleansing Prior Operation 1 4 Completed Treatment Psoriasis / Sleep Apnea, Obstructive 1 4 Not Yet Recruiting Basic Science Heart Defects,Congenital 1 4 Recruiting Treatment Transient Hypoparathyroidism 1 Not Available Completed Other Laparoscopic Hysterectomy and/or Laparoscopic Sacrocolpopexy 1 Not Available Completed Screening Colorectal Cancers 1 Not Available Recruiting Other Chronic Kidney Disease (CKD) 1 Not Available Terminated Treatment Colonoscopy 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Solution Unknown Kit Liquid Intravenous Paste Dental Injection Intrathecal Liquid Irrigation Enema Rectal Liquid Intravesical Injection, solution Intravenous Tablet, coated Oral Kit Intravenous Tablet Oral Capsule Oral Liquid Oral Solution Oral Solution Extracorporeal Solution Intravenous Solution Respiratory (inhalation) Tablet, film coated Oral Tablet, sugar coated Oral - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US7687075 No 2010-03-30 2028-06-22 US US7084130 No 2006-08-01 2021-11-29 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) Decomposes at 75 MSDS water solubility 121 g/L MSDS - Predicted Properties
Property Value Source logP -1 ChemAxon pKa (Strongest Acidic) 1.8 ChemAxon Physiological Charge -2 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 80.59 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 13.53 m3·mol-1 ChemAxon Polarizability 5.53 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available
Taxonomy
- Description
- This compound belongs to the class of inorganic compounds known as alkali metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is an alkali metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Alkali metal oxoanionic compounds
- Sub Class
- Alkali metal phosphates
- Direct Parent
- Alkali metal phosphates
- Alternative Parents
- Inorganic sodium salts / Inorganic oxides
- Substituents
- Alkali metal phosphate / Inorganic sodium salt / Inorganic oxide / Inorganic salt
- Molecular Framework
- Not Available
- External Descriptors
- sodium phosphate (CHEBI:37585)
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Not Available
- Specific Function
- Not Available
- Gene Name
- SLC20A1
- Uniprot ID
- Q8WUM9
- Uniprot Name
- Sodium-dependent phosphate transporter 1
- Molecular Weight
- 73699.01 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Virus receptor activity
- Specific Function
- Sodium-phosphate symporter which seems to play a fundamental housekeeping role in phosphate transport by absorbing phosphate from interstitial fluid for normal cellular functions such as cellular m...
- Gene Name
- SLC20A2
- Uniprot ID
- Q08357
- Uniprot Name
- Sodium-dependent phosphate transporter 2
- Molecular Weight
- 70391.755 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Sodium:phosphate symporter activity
- Specific Function
- Involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 70-80% of the apical influx.
- Gene Name
- SLC34A1
- Uniprot ID
- Q06495
- Uniprot Name
- Sodium-dependent phosphate transport protein 2A
- Molecular Weight
- 68936.53 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Sodium:phosphate symporter activity
- Specific Function
- May be involved in actively transporting phosphate into cells via Na(+) cotransport. It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the s...
- Gene Name
- SLC34A2
- Uniprot ID
- O95436
- Uniprot Name
- Sodium-dependent phosphate transport protein 2B
- Molecular Weight
- 75758.535 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Sodium:phosphate symporter activity
- Specific Function
- May be involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 20-30% of the apical influx.
- Gene Name
- SLC34A3
- Uniprot ID
- Q8N130
- Uniprot Name
- Sodium-dependent phosphate transport protein 2C
- Molecular Weight
- 63548.94 Da
References
- Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. [PubMed:12360109]
Drug created on November 30, 2015 12:10 / Updated on December 14, 2018 05:44